<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04764227</url>
  </required_header>
  <id_info>
    <org_study_id>ESO- Shanghai 17</org_study_id>
    <nct_id>NCT04764227</nct_id>
  </id_info>
  <brief_title>Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)</brief_title>
  <official_title>Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and 2-year local control rate for&#xD;
      postoperative concurrent chemoradiotherapy for esophageal squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Esophagus Cancer</condition>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Chemoradiotherapy</condition>
  <condition>Radiation Therapy</condition>
  <condition>Postoperative</condition>
  <arm_group>
    <arm_group_label>Concurrent chemoradiotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions:&#xD;
Chemotherapy: Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw*5&#xD;
Radiotherapy: A total dose of 50.4Gy will be delivered in 28 fractions at 1.8Gy/fraction, 5 fractions per week in 6 weeks. The CTV encompassed the bilateral supraclavicular, superior mediastinal, and subcarinal regions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw*5</description>
    <arm_group_label>Concurrent chemoradiotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>carboplatin AUC=2, ivgtt, d1, qw*5</description>
    <arm_group_label>Concurrent chemoradiotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>1.8Gy/d, d1-5/week, 28Fx</description>
    <arm_group_label>Concurrent chemoradiotherapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Joined the study voluntarily and signed informed consent form;&#xD;
&#xD;
          -  Age 18-75;&#xD;
&#xD;
          -  ECOG 0-2;&#xD;
&#xD;
          -  Esophageal squamous cell carcinoma, radical surgery ≤ 3 months, R0 resection;&#xD;
&#xD;
          -  The operative incision healed well;&#xD;
&#xD;
          -  T3-4N0M0, T1-4N1-3M0 (according to AJCC2009);&#xD;
&#xD;
          -  No radiotherapy, chemotherapy or other treatments pre (post) surgery;&#xD;
&#xD;
          -  PS ECOG 0-2;&#xD;
&#xD;
          -  Life expectancy of more than 3 months;&#xD;
&#xD;
          -  Hemoglobin (Hb) ≥ 9 g/dL, WBC ≥ 3 x 109/L, Neutrophils (ANC ) ≥ 1.5 x 109/L, Platelet&#xD;
             count (Pt) ≥ 100 x 109/L;&#xD;
&#xD;
          -  Hepatic function: ALAT and ASAT &lt; 2.5 x ULN, TBIL&lt; 1.5 x ULN;&#xD;
&#xD;
          -  Renal function: creatinine &lt; 1.5 x ULN&#xD;
&#xD;
          -  No immuno-deficiency;&#xD;
&#xD;
          -  Use of an effective contraceptive for adults to prevent pregnancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Complete esophageal obstruction after surgery, Esophageal perforation, Haematemesis;&#xD;
&#xD;
          -  Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in&#xD;
             situ, who survived with no evidence disease for over 3 years;&#xD;
&#xD;
          -  Participation in other interventional clinical trials within 30 days;&#xD;
&#xD;
          -  Pregnant or breast-feeding women or people during the birth-period who refused to take&#xD;
             contraceptives;&#xD;
&#xD;
          -  Drug addiction, Alcoholism or AIDS;&#xD;
&#xD;
          -  Uncontrolled seizures or psychiatric diseases, loss of control over their own&#xD;
             behavior;&#xD;
&#xD;
          -  Unsuitable to be enrolled in the trial in the opinion of the investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuaile Zhao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kuaile Zhao</last_name>
    <phone>8621-64175590</phone>
    <email>kuaile_z@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuaile Zhao, MD</last_name>
      <phone>8621-64175590</phone>
      <email>kuaile_z@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

